ITM
Live / Registered — Registered (as of 15 Jun 2021)
What this means for you
Registered since 15 Jun 2021. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79295820
- Registration number
- 6383044
- Mark type
- Design + words
- Filed
- 28 Jul 2020
- Published for opposition
- 30 Mar 2021
- Registered
- 15 Jun 2021
- Attorney of record
- Kari Moyer-Henry
Goods and services
- Class 005 — Pharmaceuticals: Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely, lutetium-containing precursors for imaging and detection for diagnosing and monitoring cancer; solutions for radioactive labelling being medical diagnostic preparations; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope for diagnosis purposes; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC for treatment of cancer; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]; radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases
- Class 010 — Medical apparatus: Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; controlling, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators being medical instruments for radiopharmaceutical purposes
- Class 042 — Scientific and technological services: Conducting clinical trials for others at all stages and in various indications, particularly in oncology; conducting phase III clinical trials for others with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]
- Class 044 — Medical, beauty and agricultural services: Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology
Owner
Prosecution history
- 26 Nov 2021 — CHANGE OF NAME/ADDRESS REC'D FROM IB
- 15 Nov 2021 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 21 Oct 2021 — NEW REPRESENTATIVE AT IB RECEIVED
- 30 Sept 2021 — GENERIC MADRID TRANSACTION SENT TO IB
- 30 Sept 2021 — GENERIC MADRID TRANSACTION CREATED
- 15 Sept 2021 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 15 Jun 2021 — REGISTERED-PRINCIPAL REGISTER
- 05 Apr 2021 — NOTIFICATION PROCESSED BY IB
- 30 Mar 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 30 Mar 2021 — PUBLISHED FOR OPPOSITION
- 15 Mar 2021 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 10 Mar 2021 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
- 10 Mar 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 23 Feb 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 23 Feb 2021 — EXAMINER'S AMENDMENT ENTERED